Overseeing high-profile public offerings for an underwriting syndicate and advising issuers on both debt and equity follow-on offerings, Goodwin draws upon strong multi-jurisdictional capabilities and substantial bench-strength. The practice mainly represents private companies in complex financings and IPOs, alongside supporting public corporations in their SEC reporting and corporate governance proceedings. Edwin O’Connor heads the New York offering, being a specialist in the tech and life sciences sectors, while Silicon Valley-based Bradley Weber is highly knowledgeable in IPOs and PIPEs. From Boston, Joseph Theis is an expert in securities law and SEC compliance measures, Robert Puopolo stands out for his M&A and joint venture work, and both Marishka DeToy and Gabriela Morales-Rivera are also cited as key for their coverage of SEC compliance and venture capital financing matters.
Legal 500 redaktioneller Kommentar

Referenzen

Unabhängig vom Legal 500-Forschungsteam zusammengestellt.

  • 'Goodwin's reputation precedes it in every way - they are a formidable competitor with deep, impressive relationships.'

Kernmandanten

  • Upstream Bio
  • Bicara Therapeutics
  • MBX Biosciences
  • Centessa Pharmaceuticals
  • Monte Rosa Therapeutics
  • ProMIS Neurosciences
  • CRISPR Therapeutics
  • Cabaletta Bio
  • Astera Labs
  • Septerna

Highlight-Mandate

  • Advised Upstream Bio in their $293 million initial public offering.
  • Advised Bicara Therapeutics in its upsized $362 million initial public offering.
  • Advised Astera Labs in its upsized $774 million initial public offering.

Anwält*innen

Praxisleitung

Edwin O’Connor; Bradley Weber; James P.C. Barri

Weitere Kernanwält*innen

Joseph Theis; Robert Puopolo; Marishka DeToy; Gabriela Morales-Rivera